Novartis AG

Products

Category

Product

Brand

Description

Viral Vector and Plasmid DNA (BIO192B)

Kymriah		Kymriah is a biosynthetically produced CAR T-cell therapy for treating acute lymphoblastic leukemia patients. Lentiviral is the vector used to make Kymriah.
ZOLGENSMA		Kymriah is a biosynthetically produced gene therapy used to treat Spinal muscular atrophy. Adeno-associated virus is the vector used to make Zolgensma.
AAV9 Platform		Novartis gene therapy platform using a particular type of adeno-associated virus (AAV) known as AAV9. This virus has distinct characteristics and can be adapted to potentially address different rare monogenic diseases using the same scientific approach and technology.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.